Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acer Therapeutics Inc (ACER)

Acer Therapeutics Inc (ACER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,746
  • Shares Outstanding, K 10,095
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,280 K
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.49
  • Number of Estimates 5
  • High Estimate -0.41
  • Low Estimate -0.61
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +42.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.08 +18.18%
on 11/14/19
4.10 -11.22%
on 12/09/19
+0.24 (+7.06%)
since 11/13/19
3-Month
2.77 +31.54%
on 10/02/19
4.10 -11.22%
on 12/09/19
+0.37 (+11.31%)
since 09/13/19
52-Week
1.87 +94.55%
on 08/16/19
28.25 -87.11%
on 04/11/19
-15.34 (-80.82%)
since 12/13/18

Most Recent Stories

More News
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Acer Therapeutics, Mammoth Energy, ProPetro, and Eldorado Resorts and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating certain officers and directors of Acer Therapeutics, Inc. (NASDAQ: ACER), Mammoth Energy Services, Inc. (NASDAQ:...

ACER : 3.64 (-2.41%)
TUSK : 1.66 (-4.05%)
PUMP : 10.00 (+0.10%)
ERI : 54.89 (+0.07%)
Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant...

ACER : 3.64 (-2.41%)
Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant...

ACER : 3.64 (-2.41%)
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm

Bragar Eagel & Squire is investigating certain officers and directors of Mammoth Energy Services, Inc. (NASDAQ: TUSK), Acer Therapeutics, Inc. (NASDAQ: ACER), Realogy Holdings Corp. (NYSE: RLGY), and AxoGen,...

TUSK : 1.66 (-4.05%)
ACER : 3.64 (-2.41%)
RLGY : 10.82 (+1.22%)
AXGN : 16.90 (-0.47%)
FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Acer Therapeutics Inc. ("Acer" or the "Company") (NASDAQ: ACER) and certain...

ACER : 3.64 (-2.41%)
Shareholder Alert: Robbins Arroyo LLP Reminds Investors Acer Therapeutics Inc. (ACER) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Acer Therapeutics Inc. (NASDAQ: ACER) filed a class action complaint for alleged violations of the Securities Exchange...

ACER : 3.64 (-2.41%)
FRIDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Acer Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Acer Therapeutics Inc. ("Acer" or "the Company") (NASDAQ: ACER) for violations...

ACER : 3.64 (-2.41%)
KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for ACER THERAPEUTICS, INC. Investors - ACER

Kessler Topaz Meltzer & Check, LLP reminds Acer Therapeutics, Inc. (Nasdaq: ACER) ("Acer") investors that a securities fraud class action lawsuit has been filed in the United States District Court for...

ACER : 3.64 (-2.41%)
ACER IMMINENT DEADLINE: Rosen, A Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Acer Therapeutics Inc.; Important August 30th Deadline - ACER

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acer Therapeutics Inc. (NASDAQ: ACER) from September 25, 2017...

ACER : 3.64 (-2.41%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acer Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ACER

Pomerantz LLP announces that a class action lawsuit has been filed against Acer Therapeutics, Inc. ("Acer" or the "Company") (NASDAQ: ACER) and certain of its officers. The class action, filed in United...

ACER : 3.64 (-2.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ACER with:

Business Summary

Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics,...

See More

Key Turning Points

2nd Resistance Point 3.79
1st Resistance Point 3.72
Last Price 3.64
1st Support Level 3.57
2nd Support Level 3.50

See More

52-Week High 28.25
Fibonacci 61.8% 18.17
Fibonacci 50% 15.06
Fibonacci 38.2% 11.95
Last Price 3.64
52-Week Low 1.87

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar